Generic Edarbi Availability
Last updated on Jan 8, 2025.
Edarbi is a brand name of azilsartan medoxomil, approved by the FDA in the following formulation(s):
EDARBI (azilsartan kamedoxomil - tablet;oral)
-
Manufacturer: AZURITY
Approval date: February 25, 2011
Strength(s): EQ 40MG MEDOXOMIL [RLD], EQ 80MG MEDOXOMIL [RLD]
Has a generic version of Edarbi been approved?
No. There is currently no therapeutically equivalent version of Edarbi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Edarbi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,157,584
Patent expiration dates:
- May 22, 2025✓
- May 22, 2025
-
Patent 7,572,920
Patent expiration dates:
- January 7, 2025✓✓
- January 7, 2025
-
Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Patent 9,066,936
Issued: June 30, 2015
Inventor(s): Yoneyama Shuji & Tanoue Yutaka
Assignee(s): Takeda Pharmaceutical Company LimitedThe present invention provides a solid pharmaceutical composition containing compound (I) having an angiotensin II receptor antagonistic action and defined in the specification and a pH control agent, which composition is superior in the stability and dissolution property of compound (I).
Patent expiration dates:
- March 26, 2028✓
- March 26, 2028
More about Edarbi (azilsartan medoxomil)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (45)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: angiotensin receptor blockers
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
